top of page

Meet Our Team

Our team benefits from decades of know-how and experiences gathered in academic institutions, technology transfer and industrial companies. Using this knowledge, we are developing a pool of highly potent biotech projects originating in academia and finding commercial partners for them.

Jiří Moos

Jiří Moos

CEO, Board of Directors

Jiří Moos is the Executive Director at i&i Prague.

Iva Machová

Iva Machová

Project Manager

Iva Machová is a Project Manager at i&i Prague.

Martin Kovalčík

Martin Kovalčík

Communications

Martin Kovalčík is our Communications Manager.

Milan Prášil

Milan Prášil

Chairman, Board of directors

Milan Prášil is the Chairman of the Board of Directors.

Jiří Růžička

Jiří Růžička

Project Manager

Jiri Ruzicka is a Project manager at i&i Prague.

Simona Šandová

Simona Šandová

Office Manager

Simona Šandová is the Office Manager of i&i Prague.

David Stíbal

David Stíbal

Board of Directors, Vice Director

David Stíbal is the Vice Director at i&i Prague.

Roberto Fernandez

Roberto Fernandez

Project Manager

Roberto Fernandez is a Project manager at i&i Prague.

Mikuláš Vargic

Mikuláš Vargic

External Lawyer

Mikuláš studied law at Masaryk University Brno and International and European Law at the University of Antwerp.

Our Mission

We scout and support the growth through discovery, pre-seed or seed phase of the most promising projects with innovative potential in Drug Discovery, Diagnostics, MedTech and other Life Science fields. 

Our Objective

Our ambition is to become a leading partner advancing and promoting game-changing biotech inventions coming from the Central Europe region.

Our Team

Our team benefits from expertise and experience gathered from IOCB and IOCB Tech. We are developing a pool of highly promising biotech projects originating from academia and finding commercial partners for them.

IMG_9614.jpg

Our background

We operate as a private company under the wings of the Czech Academy of Sciences and its Institute of Organic Chemistry and Biochemistry (IOCB). From 1994 to 2002, the IOCB was led by Dr. Antonín Holý, whose team invented and developed hugely effective and successful anti-HIV drugs (Truvada, Atripla, Complera, Eviplera). We believe that this is a legacy to build upon and that, with your and our combined expertise, we can make this world a better place and help millions of people.

bottom of page